Open‑label Brexpiprazole fMRI Trial in Adults With Major Depressive Disorder and Anxiety
Sponsor ID
331-201-00376
Clinicaltrials.gov ID
EudraCT ID
N/A
EUCTIS ID
N/A
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Study Contact Information
N/A
Terminated/Withdrawn
Sponsor ID
331-201-00376
Study Summary
The purpose of this study is to use fMRI to evaluate the effects of brexpiprazole as add-on therapy to antidepressants on brain connectivity in individuals with MDD and symptoms of anxiety, aged 18 to 65.
Inclusion and Exclusion Criteria
Inclusion Criteria
- * 18 to 65 year of age
- * Major Depressive Disorder (MDD) with symptoms of anxiety
Exclusion Criteria
- * Contraindicated to perform fMRI scan
- * Previous exposure to brexpiprazole
Inclusion and Exclusion Criteria
Inclusion Criteria:
- 18 to 65 year of age
- Major Depressive Disorder (MDD) with symptoms of anxiety
- Stable treatment with less than 50% improvement
Exclusion Criteria:
- Contraindicated to perform fMRI scan
- Previous exposure to brexpiprazole
Locations
No locations found.